NADPH oxidase 1/4 dual inhibitor setanaxib suppresses platelet activation and thrombus formation.

Aims: The production of reactive oxygen species (ROS) by NADPH oxidase (NOX) is able to induce platelet activation, making NOX a promising target for antiplatelet therapy. In this study, we examined the effects of setanaxib, a dual NOX1/4 inhibitor, on human platelet function and ROS-related signaling pathways.

Materials And Methods: In collagen-stimulated human platelets, aggregometry, assessment of ROS and Ca, immunoblotting, ELISA, flow cytometry, platelet adhesion assay, and assessment of mouse arterial thrombosis were performed in this study.